Trial · NCT06746701
Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
NCT06746701, Recruiting, Xiangya Hospital of Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA. Trials, record NCT06746701. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06746701
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- NCT number
- NCT06746701
- Status
- Recruiting
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Xiangya Hospital of Central South University
- Conditions
- HBV
- Interventions
- Peg-IFNα-2b combined with NA, Nucleotide Analogues
- First posted
- 2024-12-24
- Last updated
- 2024-12-24
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate | through study completion, an average of 24 weeks. | The definition of a cure is: maintaining HBsAg(Hepatitis B surface antigen) negativity (with or without the appearance of anti-HBs), undetectable HBV DNA, normal liver biochemical indices, and improvement in liver tissue lesions after discontinuation of treatment. |
| Primary | Liver cancer incidence rate | through study completion, an average of 24 weeks. | |
| Secondary | The decrease in HBsAg compared to baseline. | through study completion, an average of 24 weeks. | |
| Secondary | HBsAg seroconversion rate | through study completion, an average of 24 weeks. | |
| Secondary | Changes of biomarkers after disease progression-related markers such as HBV DNA quantification compared to baseline. | through study completion, an average of 24 weeks. | |
| Secondary | Incidence of abnormal and clinically relevant changes in vital signs | through study completion, an average of 24 weeks. | |
| Secondary | Incidence of treatment-emergent adverse event (AE) | through study completion, an average of 24 weeks. | |
| Secondary | Incidence of abnormal and clinically relevant changes in laboratory assessments | through study completion, an average of 24 weeks. | |
| Secondary | Incidence of severe acute allergic reactions occurring during treatment. | through study completion, an average of 24 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06746701
GET https://conductscience.org/api/trials/v1/NCT06746701/registered